Adherium will provide its Hailie® Smartinhaler®for an AstraZeneca clinical trial

Share this news:

Adherium Limited (“Adherium” or “the Company”; ASX:ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that AstraZeneca has selected its Hailie® Smartinhaler® platform for a clinical trial. This contract is valued at $1.1M over the course of three years.

AstraZeneca’s inhaled medication use will be recorded and transferred via Hailie Smartinhaler devices.

Adherium CEO, Dr. Paul Mastoridis, said: “This agreement underscores Adherium's strategic commitment to enhancing patient care through advanced technology. Our Hailie® platform is designed to ensure precise monitoring and support for patients with respiratory diseases, facilitating the pursuit of tailored therapy."

Adherium will be providing Hailie® Smartinhalers®, Hailie® app and Platform for the trial, allowing for accurate tracking of inhaler medication use through the selected eCOA (Electronic Clinical Outcome Assessment) devices.

Release ID: 89130850

REVIEWED BY
Editor Profile Picture
This content is reviewed by our News Editor, WL Tan.

If you need any help with this piece of content, please contact us through our contact form
SUBSCRIBE FOR MORE